Small molecule · Inhibitor of FGFR1, FGFR2 and FGFR3 · developed by Tyra Biosciences
TYRA-200 is an oral tyrosine kinase inhibitor of FGFR1, FGFR2 and FGFR3. It is designed to target tumors that carry activating gene alterations of FGFR2. It is being studied in cholangiocarcinoma and other solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06160752 | Phase 1 | Locally Advanced Cholangiocarcinoma | Active not recruiting | TYRA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Intrahepatic CholangiocarcinomaLocally Advanced CholangiocarcinomaMetastatic CholangiocarcinomaSolid Tumor
Updated Nov 1, 2026. Something wrong or missing? Report it on the TYRA page.
See TYRA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TYRA catalysts and pipeline →